Homepage
Author:
BioInvent International
Posted Date:
April 21, 2026
BioInvent to Present Data of BI-1808 Plus KEYTRUDA(R) (Pembrolizumab) in Recurrent Ovarian Cancer at the 2026 ASCO Annual Meeting
BioInvent International
April 21, 2026
BioInvent International AB Publishes Annual Report 2025
BioInvent International
March 31, 2026
BioInvent Achieves Phase 3 Milestone for HMI-115 in Endometriosis
BioInvent International
March 26, 2026
BioInvent International AB: Year-End Report January 1 – December 31, 2025
BioInvent International
February 26, 2026
Invitation to Presentation of BioInvent’s Year-End Report 2025
BioInvent International
February 26, 2026
BioInvent Announces Nomination of Two New Board Members Ahead of 2026 Annual General Meeting
BioInvent International
February 23, 2026
